Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer: A multi-center, open-label, single-arm, phase II study

被引：0
|
作者：
Peng, Peijian
Xu, Xiaolu
Zhong, Jincai
Lin, Hong
Wang, Hong
Ye, Jin-Hui
Du, Caiwen
Wang, Zhi-Hui
Yu, Gengsheng
Zou, Guorong
Ouyang, Jie
Wang, Yong-Xia
Li, Lu-Zhen
Xu, Fei
Cui, Shi-En
机构：
[1] Sun Yet Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Peoples R China
[3] Zhuhai Hosp Integrated Tradit Chinese & Western M, Zhuhai, Peoples R China
[4] Zhuhai Matern & Child Hlth Hosp, Dept Breast Surg, Zhuhai, Peoples R China
[5] First Peoples Hosp Zhaoqing, Zhaoqing, Peoples R China
[6] Chinese Acad Med Sci, Shenzhen Ctr, Canc Hosp, Dept Med Oncol, Shenzhen, Longgang Distri, Peoples R China
[7] Jiangmen Cent Hosp, Jiangmen, Peoples R China
[8] Panyu Cent Hosp, Guangzhou, Peoples R China
[9] Dongguan Winter Melon Hosp, Dongguan, Peoples R China
[10] Dongguan Peoples Hosp, Dongguan, Peoples R China
[11] Guangzhou Univ Tradit Chinese Med, Zhongshan Hosp Tradit Chinese Med, Zhongshan City, Peoples R China
[12] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[13] Zhongshan City Peoples Hosp, Dept Gen Surg, Zhongshan City, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13102
引用
收藏
页数：1
相关论文
共 50 条
  • [21] High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study
    Jun Li
    Qi Han
    Yanqing Huang
    Yanhui Wei
    Jie Zi
    Lidong Zhao
    Zhimei Cai
    Xuzhang Lu
    Rong Xiao
    Yanming Zhang
    Xiaotian Yang
    Hao Xu
    Naitong Sun
    Wanchuan Zhuang
    Zhengdong Wu
    Yuan Xia
    Yanli Xu
    Bin He
    Wei Zhu
    Fengling Min
    Yongchun Chen
    Banghe Ding
    Peimin Shi
    Jing Xie
    Hua Tang
    Zefa Liu
    Bingzong Li
    Yu Sun
    Hongxia Qiu
    Limin Duan
    Elanora Dovat
    Chunhua Song
    Laszlo SzeKely
    Sinisa Dovat
    Zheng Ge
    Blood Cancer Journal, 12
  • [22] High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study
    Li, Jun
    Han, Qi
    Huang, Yanqing
    Wei, Yanhui
    Zi, Jie
    Zhao, Lidong
    Cai, Zhimei
    Lu, Xuzhang
    Xiao, Rong
    Zhang, Yanming
    Yang, Xiaotian
    Xu, Hao
    Sun, Naitong
    Zhuang, Wanchuan
    Wu, Zhengdong
    Xia, Yuan
    Xu, Yanli
    He, Bin
    Zhu, Wei
    Min, Fengling
    Chen, Yongchun
    Ding, Banghe
    Shi, Peimin
    Xie, Jing
    Tang, Hua
    Liu, Zefa
    Li, Bingzong
    Sun, Yu
    Qiu, Hongxia
    Duan, Limin
    Dovat, Elanora
    Song, Chunhua
    SzeKely, Laszlo
    Dovat, Sinisa
    Ge, Zheng
    BLOOD CANCER JOURNAL, 2022, 12 (10)
  • [23] Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
    Park, Yeon Hee
    Im, Seock-Ah
    Kim, Sung-Bae
    Sohn, Joo Hyuk
    Lee, Keun Seok
    Chae, Yee Soo
    Lee, Ki Hyeong
    Kim, Jee Hyun
    Im, Young-Hyuck
    Kim, Ji-Yeon
    Kim, Tae-Yong
    Lee, Kyung-Hun
    Ahn, Jin-Hee
    Kim, Gun Min
    Park, In Hae
    Lee, Soo Jung
    Han, Hye Sook
    Kim, Se Hyun
    Jung, Kyung Hae
    EUROPEAN JOURNAL OF CANCER, 2017, 86 : 385 - 393
  • [24] Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study
    Li Yanwei
    Feng, He
    Ren, Peng
    Yue, Jie
    Zhang, Wencheng
    Tang, Peng
    Shang, Xiaobin
    Pang, Qingsong
    Liu, Dongying
    Chen, Chuangui
    Pan, Zhanyu
    Tao, Yu Zhen
    ONCOLOGIST, 2020, 25 (10): : E1464 - E1472
  • [25] LUCY: A phase IIIb, single-arm, open-label multicenter study of olaparib in patients with HER2-negative metastatic breast cancer and a germline BRCA1/2 mutation
    Gelmon, Karen
    Walker, Graham P.
    Fisher, Graham V.
    CANCER RESEARCH, 2018, 78 (04)
  • [26] Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: Updated results of a multi-center, single-arm, phase 2 trial
    Zhao, Wensi
    Li, Jun
    Li, Liping
    Huang, Junping
    Gong, Wei
    Yu, Xiongjie
    Le, Kefa
    He, Linli
    Han, Qi
    Wang, Songlin
    Tang, Ze
    Li, Wenbin
    Hua, Xianliang
    Chen, Yongshun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study
    Ortega, Vanesa
    Anton, Antonio
    Garau, Isabel
    Afonso, Nomia
    Calvo, Lourdes
    Fernandez, Yolanda
    Martinez-Garcia, Maria
    Blanco, Esperanza
    Zamora, Pilar
    Garcia, Mirta
    Juan Illarramendi, Jose
    Rodriguez Sanchez, Csar Augusto
    Sampayo, Miguel
    Aguirre, Elena
    Manuel Perez-Garcia, Jose
    Cortes, Javier
    Llombart-Cussac, Antonio
    CLINICAL BREAST CANCER, 2019, 19 (02) : 105 - 112
  • [28] Results of a phase 2, multicenter, single-arm study of eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer
    Vandat, L.
    Schwartzberg, L.
    Gluck, S.
    Rege, J.
    Liao, J.
    Cox, D.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2012, 72
  • [29] Balixafortide (a CXCR4 antagonist) plus eribulin in HER2-negative metastatic breast cancer (MBC): A Phase I open-label trial
    Kaufman, P. A.
    Pernas, S.
    Martin, M.
    Gil-Martin, M.
    Gomez Pardo, P.
    Sara, L. T.
    Manso, L.
    Ciruelos, E.
    Perez-Fidalgo, J. A.
    Hernando, C.
    Ademuyiwa, F. O.
    Weilbaecher, K.
    Mayer, I.
    Pluard, T. J.
    Martinez Garcia, M.
    Vahdat, L.
    Wach, A.
    Barker, D.
    Romagnoli, B.
    Cortes, J.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S117 - S118
  • [30] Eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer: Results of a phase 2, multicenter, single-arm study
    Mcintyre, K.
    O'Shaughnessy, J.
    Schwartzberg, L.
    Glueck, S.
    Berrak, E.
    Song, J.
    Rege, J.
    Cox, D.
    Vahdat, L.
    CANCER RESEARCH, 2013, 73
12345